Compare Natera Inc. Common Stock (NTRA) vs Snowflake Inc (SNOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Snowflake Inc — how do they compare? Natera Inc. Common Stock trades at $394 (market cap $57.03B), while Snowflake Inc trades at $329.88 (market cap $126.22B). The key difference: Snowflake Inc is far larger — about 2.2× Natera Inc. Common Stock's market cap, and Snowflake Inc is more actively traded (4,112,138 versus 1,131,157). Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Snowflake Inc for 53 Days on average.
| NTRA | SNOW | |
|---|---|---|
Market Cap | $57.03B | $126.22B |
Volume | 1,131,157 | 4,112,138 |
Sector | Health | Technology |
52-Week High | $425.64 | $368.89 |
52-Week Low | $179.42 | $121.11 |
Typical Hold Time | 0 Days | 53 Days |
Enterprise Value | $56.18B | $126.64B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Snowflake (SNOW) trades at $335.08, down 7.02% amid market volatility, but maintains strong analyst support with 81% buy ratings and a $418.03 consensus target. The company shows robust revenue growth, reaching $3.63 billion in 2025, though it remains unprofitable with a -20.07% net margin. Recent technical indicators are bullish on moving averages, while oscillators remain neutral. Key developments include a $3.75 billion convertible note offering and expanded partnerships with UiPath.
Outlook remains positive given strong revenue trajectory and analyst confidence, but risks include persistent losses, high valuation multiples (P/S 22.66), and competitive pressures. The stock offers growth potential if profitability improves, yet investors must weigh execution risks against long-term AI data cloud opportunities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Snowflake Inc
Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that came public in 2020. To date, the company has over 3,000 customers including nearly 30% of the Fortune 500 as its customers. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to easily buy and ingest data almost instantaneously compared with a traditionally months-long process. Overall, the company is known for the fact that all of its data solutions that can be hosted on various public clouds.
Read more on SNOW →
